SCHEMBL1855582

SCHEMBL1855582

FC(F)(F)c1ccc2c(c1)Nc1ccccc1S2.O=C(Cl)Cl

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 12/20 0.83
CYBB P04839 2/20 0.83
NOX3 Q9HBY0 2/20 0.83
NOX4 Q9NPH5 2/20 0.83
MAPT P10636 7/20 0.54
ALOX15 P16050 4/20 0.54
ALDH1A1 P00352 2/20 0.54
HSD17B10 Q99714 2/20 0.54
HPGD P15428 1/20 0.54
GAA P10253 6/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
SNCA P37840 3/20 0.54
APP P05067 1/20 0.54
USP2 O75604 1/20 0.53
BCHE P06276 2/20 0.53
ACHE P22303 2/20 0.53
TDP1 Q9NUW8 2/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenothiazine SCHEMBL6532335 0.91 NOX1 (1.00) NOX1CYBBNOX3NOX4MAPT
SCHEMBL560225 0.91 NOX1 (1.00) NOX1CYBBNOX3NOX4MAPT
SCHEMBL29475150 0.91 NOX1 (1.00) NOX1CYBBNOX3NOX4MAPT
Benzene SCHEMBL29242186 0.90 NOX1 (0.97) NOX1CYBBNOX3NOX4MAPT
SCHEMBL30811565 0.83 NOX1 (0.84) NOX1CYBBNOX3NOX4MAPT
SCHEMBL10372692 0.83 NOX1 (0.84) NOX1CYBBNOX3NOX4MAPT
Phenothiazine SCHEMBL1509832 0.81 NOX1 (0.74) NOX1CYBBNOX3NOX4MAPT
SCHEMBL11811857 0.80 NOX1 (0.57) NOX1CYBBNOX3NOX4MAPT
SCHEMBL1509893 0.79 NOX1 (0.84) NOX1CYBBNOX3NOX4MAPT
SCHEMBL1856709 0.78 NOX1 (0.61) NOX1CYBBNOX3NOX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317454-B1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2011-05-25 EP disclosed
US-6800619-B2 UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES VERTEX PHARMACEUTICALS INCORPORATED 2004-10-05 US disclosed
EP-1317454-A2 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2003-06-11 EP disclosed
US-20020058630-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2002-05-16 US disclosed
WO-2002022611-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058630-A1 Caspase inhibitors and uses thereof CASP2, CASP3, CASP7 NOX1 2272/4885CYBB 2761/4885NOX3 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.